Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 May;27(5):835-846.
doi: 10.1038/s41556-025-01650-9. Epub 2025 Apr 21.

Tumour interstitial fluid-enriched phosphoethanolamine suppresses T cell function

Affiliations

Tumour interstitial fluid-enriched phosphoethanolamine suppresses T cell function

Yupeng Wang et al. Nat Cell Biol. 2025 May.

Abstract

Nutrient stress represents an important barrier for anti-tumour immunity, and tumour interstitial fluid often contains metabolites that hinder immune function. However, it is difficult to isolate the effects of tumour nutrient stress from other suppressive factors. Thus, we used a chemically defined cell culture medium based on the metabolomic profile of tumour interstitial fluid: tumour interstitial fluid medium (TIFM). Culture of CD8+ T cells in TIFM limited cell expansion and impaired CD8+ T cell effector functions upon restimulation, suggesting that tumour nutrient stress alone is sufficient to drive T cell dysfunction. We identified phosphoethanolamine (pEtn), a phospholipid intermediate, as a driver of T cell dysfunction. pEtn dampened T cell receptor signalling by depleting T cells of diacylglycerol required for T cell receptor signal transduction. The reduction of pEtn accumulation in tumours improved intratumoural T cell function and tumour control, suggesting that pEtn accumulation plays a dominant role in immunosuppression in the tumour microenvironment.

PubMed Disclaimer

Conflict of interest statement

Competing interests: G.M.D. declares competing financial interests and has submitted patents targeting exhausted T cells that are licensed or pending and is entitled to a share in net income generated from licensing of these patent rights for commercial development. G.M.D. consults for and/or is on the scientific advisory board of BlueSphere Bio, Novasenta, Xyphos and Kalivir Immunotherapeutics; has grants from Novasenta, Astellas, RemplirBio and Kalivir; and owns stock in Novasenta, BlueSphere Bio and RemplirBio. The other authors declare no competing interests.

References

    1. Pagès, F. et al. Immune infiltration in human tumors: a prognostic factor that should not be ignored. Oncogene 29, 1093–1102 (2010). - PubMed - DOI
    1. Dahlin, A. M. et al. Colorectal cancer prognosis depends on T-cell infiltration and molecular characteristics of the tumor. Mod. Pathol. 24, 671–682 (2011). - PubMed - DOI
    1. Ribas, A. & Wolchok, J. D. Cancer immunotherapy using checkpoint blockade. Science 359, 1350–1355 (2018). - PubMed - PMC - DOI
    1. Ai, L. et al. Research status and outlook of PD-1/PD-L1 inhibitors for cancer therapy. Drug Des. Dev. Ther. 14, 3625–3649 (2020). - DOI
    1. Sambi, M., Bagheri, L. & Szewczuk, M. R. Current challenges in cancer immunotherapy: multimodal approaches to improve efficacy and patient response rates. J. Oncol. 2019, 4508794 (2019). - PubMed - PMC - DOI

MeSH terms

LinkOut - more resources